BR0214430A - Formulação de aminoácidos e riboflavina úteis para reduzir efeitos tóxicos de quimioterapia citotóxica - Google Patents

Formulação de aminoácidos e riboflavina úteis para reduzir efeitos tóxicos de quimioterapia citotóxica

Info

Publication number
BR0214430A
BR0214430A BR0214430-1A BR0214430A BR0214430A BR 0214430 A BR0214430 A BR 0214430A BR 0214430 A BR0214430 A BR 0214430A BR 0214430 A BR0214430 A BR 0214430A
Authority
BR
Brazil
Prior art keywords
cytotoxic chemotherapy
cancer
amino acids
toxic effects
pharmaceutical compositions
Prior art date
Application number
BR0214430-1A
Other languages
English (en)
Inventor
Stanislaw R Burzynski
Original Assignee
Stanislaw R Burzynski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanislaw R Burzynski filed Critical Stanislaw R Burzynski
Publication of BR0214430A publication Critical patent/BR0214430A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMULAçãO DE AMINOáCIDOS E RIBOFLAVINA úTEIS PARA REDUZIR EFEITOS TóXICOS DE QUIMIOTERAPIA CITOTóXICA". São divulgadas composições farmacêuticas eficazes para o alivio ou para a redução dos efeitos de fadiga e de fraqueza associados ao câncer e à quimioterapia citotóxica contra o câncer. As composições farmacêuticas da presente invenção compreendem riboflavina, efectores do ciclo da uréia em forma livre ou de sais farmacologicamente aceitáveis dos mesmos e aminoácidos selecionados do grupo de aminoácidos essenciais e não-essenciais, em forma livre ou de sais farmaceuticamente aceitáveis dos mesmos, adequadamente combinados com veículos, diluentes ou excipientes apropriados. Também são divulgados métodos para o alívio ou para a redução dos efeitos de fadiga e de fraqueza associados ao câncer e à quimioterapia citotóxica contra o câncer por administração de composições farmacêuticas da presente invenção.
BR0214430-1A 2001-11-27 2002-11-21 Formulação de aminoácidos e riboflavina úteis para reduzir efeitos tóxicos de quimioterapia citotóxica BR0214430A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/995,010 US20030105104A1 (en) 2001-11-27 2001-11-27 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
PCT/US2002/037354 WO2003045372A1 (en) 2001-11-27 2002-11-21 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy

Publications (1)

Publication Number Publication Date
BR0214430A true BR0214430A (pt) 2004-11-03

Family

ID=25541300

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214430-1A BR0214430A (pt) 2001-11-27 2002-11-21 Formulação de aminoácidos e riboflavina úteis para reduzir efeitos tóxicos de quimioterapia citotóxica

Country Status (21)

Country Link
US (2) US20030105104A1 (pt)
EP (1) EP1450781B1 (pt)
JP (1) JP4614660B2 (pt)
KR (1) KR100953483B1 (pt)
CN (1) CN100358527C (pt)
AT (1) ATE330595T1 (pt)
BR (1) BR0214430A (pt)
CA (1) CA2468133C (pt)
DE (1) DE60212693T2 (pt)
EA (1) EA009516B1 (pt)
HU (1) HU230986B1 (pt)
IL (2) IL162141A0 (pt)
MX (1) MXPA04004994A (pt)
NO (1) NO332858B1 (pt)
NZ (1) NZ532833A (pt)
PL (1) PL353656A1 (pt)
RO (1) RO121173B1 (pt)
SI (1) SI21542A (pt)
UA (1) UA78977C2 (pt)
WO (1) WO2003045372A1 (pt)
ZA (1) ZA200404115B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100413866C (zh) * 2002-08-02 2008-08-27 中国人民解放军军事医学科学院放射医学研究所 核黄素衍生物及其制备方法与应用
US20060035981A1 (en) * 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
US20070248693A1 (en) * 2003-08-02 2007-10-25 Elizabeth Mazzio Nutraceutical composition and method of use for treatment / prevention of cancer
ES2537974T3 (es) * 2004-11-26 2015-06-16 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para el tratamiento de la encefalopatía hepática
JP5033802B2 (ja) * 2005-09-19 2012-09-26 オムニビジョン テクノロジーズ， インコーポレイテッド タスク型画像化システム
CA2645833C (en) * 2006-03-15 2014-12-30 Suntory Limited Compositions containing riboflavin and sesamin-class compounds
WO2008050836A1 (fr) * 2006-10-25 2008-05-02 Ajinomoto Co., Inc. Agent destiné à l'amélioration des effets secondaires d'un agent chimiothérapeutique
WO2008105384A1 (ja) * 2007-02-26 2008-09-04 Kyowa Hakko Bio Co., Ltd. シトルリン含有錠剤
JP5591533B2 (ja) 2007-03-15 2014-09-17 サントリーホールディングス株式会社 抗疲労剤
WO2010011927A1 (en) 2008-07-25 2010-01-28 Noventis, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
CA2737619A1 (en) 2008-09-19 2010-03-25 Nestec S.A. Nutritional support of the immune system during anti-cancer treatment
AU2014200578B2 (en) * 2008-09-19 2016-08-11 Société des Produits Nestlé S.A. Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
PT3686183T (pt) 2009-04-03 2022-10-03 Ocera Therapeutics Inc Fenilacetato de l-ornitina e métodos de preparação do mesmo
US20120157526A1 (en) 2009-06-08 2012-06-21 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
US8449512B2 (en) 2010-04-09 2013-05-28 Davinci Biomedical Research Products Inc. Stoma stabilitating device and method
EP2397458A1 (en) * 2010-06-21 2011-12-21 Lunamed AG Organic salts and co-crystals of phenylbutyric acid
JP2013532661A (ja) 2010-07-22 2013-08-19 リベン ファーマシューティカルズ インコーポレイテッド 磁気双極子安定化溶液の使用を含む疾患を処置または改善する方法および行動を向上させる方法
KR102069790B1 (ko) * 2010-09-24 2020-01-23 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 위장 기능을 증진시키기 위한 물질 및 방법
KR101888215B1 (ko) 2010-10-06 2018-09-20 오세라 테라퓨틱스, 아이엔씨. L-오르니틴 페닐아세테이트의 제조 방법
TWI489981B (zh) * 2010-12-10 2015-07-01 柏萊迪健康科學有限責任公司 使用茉莉酸治療膀胱功能障礙
TWI551288B (zh) * 2011-02-17 2016-10-01 Ea Pharma Co Ltd Antimicrobial activity enhancer for chemotherapeutic agents
ES2630306T3 (es) * 2011-07-07 2017-08-21 Research Cancer Institute Of America Sistemas, métodos, y formulaciones para tratar el cáncer
CN110522744B (zh) 2013-03-11 2023-04-07 佛罗里达大学研究基金会有限公司 用于改善肺功能和用于预防和/或治疗辐射诱发的肺并发症的材料和方法
MX2016006006A (es) * 2013-11-08 2016-07-18 Legacy Healthcare Ltd Metodo para el manejo del cancer y para el tratamiento de las comorbilidades relacionadas con el cancer.
JP6598425B2 (ja) * 2014-02-27 2019-10-30 花王株式会社 疲労の評価方法
NZ732632A (en) 2014-11-24 2021-07-30 Ucl Business Ltd Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
CN105495582A (zh) * 2015-12-11 2016-04-20 北京康比特体育科技股份有限公司 一款抗疲劳、促恢复的保健食品氨基酸组合物
EP3621947A4 (en) 2017-05-11 2021-03-10 Ocera Therapeutics, Inc. L-ORNITHINE PHENYLACETATE MANUFACTURING PROCESSES

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
JPS58126767A (ja) * 1982-01-22 1983-07-28 Ajinomoto Co Inc 肝臓病患者用栄養組成物
DE3672950D1 (de) * 1985-10-23 1990-08-30 Mulli Kurt Nachf Gmbh Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
US5045468A (en) * 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
EP0421309B2 (en) * 1989-10-02 2001-08-16 Novartis Nutrition AG Protein hydrolysates
US5292773A (en) * 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
ES2173109T3 (es) * 1992-12-23 2002-10-16 Abbott Lab Alimentos de unso medico destinados parael sostenimiento nutricional de recien nacidos/de bebes que padecen enfermedades metabolicas.
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
FR2705765B1 (fr) * 1993-04-29 1995-08-18 Eurofours Sa Porte de four.
US5547927A (en) * 1993-05-28 1996-08-20 Abbott Laboratories Enteral nutritional product for patients undergoing radiation therapy and/or chemotherapy
NZ248605A (en) * 1993-05-28 1994-12-22 Abbott Lab Enteral nutritional product comprising protein and fat
US5719133A (en) * 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same
US5728678A (en) * 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
US5776913A (en) * 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
ATE310505T1 (de) * 1996-05-14 2005-12-15 Stanislaw R Burzynski Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität
US5817927A (en) * 1997-04-11 1998-10-06 Betzdearborn Inc. Method and apparatus for monitoring water process equipment
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
ES2205646T3 (es) 1999-06-26 2004-05-01 B. Braun Melsungen Ag Solucion acuosa para la nutricion parenteral.
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
US6377094B1 (en) * 2002-03-25 2002-04-23 Oak Technology, Inc. Arbitrary waveform synthesizer using a free-running ring oscillator

Also Published As

Publication number Publication date
HUP0402240A2 (hu) 2005-02-28
NZ532833A (en) 2006-12-22
ZA200404115B (en) 2005-11-30
MXPA04004994A (es) 2005-04-08
DE60212693T2 (de) 2007-07-05
KR100953483B1 (ko) 2010-04-16
CN1596109A (zh) 2005-03-16
KR20040065565A (ko) 2004-07-22
EA009516B1 (ru) 2008-02-28
US20030105104A1 (en) 2003-06-05
IL162141A (en) 2009-05-04
CA2468133C (en) 2011-02-22
AU2002352843A1 (en) 2003-06-10
IL162141A0 (en) 2005-11-20
EP1450781A1 (en) 2004-09-01
CA2468133A1 (en) 2003-06-05
US20050182064A1 (en) 2005-08-18
NO20042364L (no) 2004-06-07
HU230986B1 (hu) 2019-08-28
US7427619B2 (en) 2008-09-23
RO121173B1 (ro) 2007-01-30
DE60212693D1 (de) 2006-08-03
EA200400737A1 (ru) 2004-12-30
JP4614660B2 (ja) 2011-01-19
PL353656A1 (en) 2003-06-02
JP2005518361A (ja) 2005-06-23
CN100358527C (zh) 2008-01-02
WO2003045372A1 (en) 2003-06-05
NO332858B1 (no) 2013-01-21
ATE330595T1 (de) 2006-07-15
EP1450781B1 (en) 2006-06-21
UA78977C2 (en) 2007-05-10
SI21542A (sl) 2005-02-28
HUP0402240A3 (en) 2012-09-28

Similar Documents

Publication Publication Date Title
BR0214430A (pt) Formulação de aminoácidos e riboflavina úteis para reduzir efeitos tóxicos de quimioterapia citotóxica
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
WO2001098290A3 (en) Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
IL159843A0 (en) Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
BR0211742A (pt) Derivados de aminoisoxazole ativos como inibidores de cinase
BR0009042A (pt) Composto, uso do mesmo, processo para prepararum composto, composição farmacêutica, e, métodospara tratar uma doença em um animal em que aatividade de cisteìna protease contribui para apatologia e/ou sintomatologia da doença, e paratratar uma doença em um animal em que a atividadede catepsina s contribui para a patologia e/ousintomatologia da doença
BR0211289A (pt) Derivados de dolastatina 10
HUP0302319A2 (hu) Gyógyszerkészítmények gyógyászati hatóanyagok szájon át történő bejuttatására
JP2006508953A5 (pt)
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
NO20063277L (no) Farmasoytisk sammensetning av vinflunin som er ment for parenteral administrering, fremstillingsmate og anvendelse derav
BR0314450A (pt) Sais de ácido borÈnico com adição de uma base farmaceuticamente aceitável, formulação farmacêutica, e uso dos referidos sais para preparar uma formulação farmacêutica
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
BR0212036A (pt) Composições farmacêuticas compreendendo conjugados de polissacarìdeos para a inibição da metástase ou prevenção da recorrência de tumor maligno
WO2006031719A3 (en) 1,4-bis-n-oxide-5,8-dihydroxyanthracenedione compounds and the use thereof
BRPI0414139A (pt) métodos e composições para tratar infecções por herpes
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
CA2420640A1 (en) Combination preparations of 3-n-formyl hydroxy amino propyl phosphonic acid derivatives or 3-n-acetyl hydroxy amino propyl phosphonic acid derivatives together with special pharmaceutical active ingredients
BRPI0414148A (pt) derivados de imidazol
WO2004058303A3 (en) Compositions of benzoquinolizine carboxylic acid antibiotic drugs
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv
BR0011845A (pt) Complexo farmacêutico
MX2023001572A (es) Formas farmaceuticas sólidas de palbociclib.
AU2003218141A1 (en) Potent, simplified derivatives of immunosuppressive agents

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/198 (2006.01), A61K 31/195 (2006.01), A61K